Characterization of Advanced RAS -driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues
The Journal of Clinical Endocrinology & Metabolism · 2026
DOI: 10.1210/clinem/dgaf366 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Sarah Hamidi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Adenocarcinoma, Follicular, Thyroid Carcinoma, Anaplastic, ras Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Context
With novel RAS-targeted therapies emerging, better understanding of RAS-driven differentiated (DTC) and anaplastic (ATC) thyroid cancers is warranted.
Objective
Characterize the genotypic and phenotypic landscape of RAS-driven DTC and ATC and review current and future therapeutic avenues.
Design
Retrospective chart review between January 2015 and June 2023. Median follow-up duration 8.4 years in DTC cohort and 36.4 months in ATC cohort.
Setting
Single-center study at MD Anderson Cancer Center. Patients Individuals with RAS-altered DTC or ATC identified before kinase inhibitor exposure.
Interventions
None. Main Outcome Measures Primary objective was to describe clinical and molecular characteristics. Secondary objectives included identifying prognostic factors and assessing survival outcomes with available therapies.
Results
Among 120 RAS-driven DTC and 71 RAS-driven ATC, NRAS was the most common alteration (69% of DTC, 70% of ATC), mainly at residue Q61. Brain metastases were found in 22% of patients undergoing brain imaging (19% in DTC, 25% in ATC). Median overall survival (OS) was 15.2 years in DTC, with 49% of patients receiving at least 1 line of systemic therapy, most commonly lenvatinib (66%). Median time to systemic therapy was 3.5 years from diagnosis, and median OS from therapy initiation was 6.0 years. In ATC, median OS was 7.5 months. Stage IVC [hazard ratio (HR) = 6.78)], neck surgery (HR = 0.29), and exposure to immunotherapy (HR = 0.13) were significantly associated with mortality.
Conclusion
Advanced RAS-driven follicular-derived thyroid cancers seem to exhibit an aggressive behavior, particularly in ATC, in which prognosis remains poor despite expert multidisciplinary care. Advances in RAS-targeted therapies offer hope for improved therapeutic options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Thoracic-Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
ORCID-Profile: Sarah Hamidi, Anastasios Maniakas, Neal S Akhave, Victoria E Banuchi, Naifa L Busaidy, Ramona Dadu, Renata Ferrarotto, Marie-Claude Hofmann, S Mohsen Hosseini, Mimi I Hu, Priyanka C Iyer, Mena Mansour, Vicente R Marczyk, Sinchita Roy-Chowdhuri, Steven I Sherman, Mark E Zafereo, Steven G Waguespack, Maria E Cabanillas
Förderung
- NCI NIH HHS
Zitieren
APA
Hamidi, S., Maniakas, A., Akhave, N. S., Banuchi, V. E., Busaidy, N. L., Dadu, R., Ferrarotto, R., Guise, T. A., Hofmann, M. C., Hosseini, S. M., Hu, M. I., Iyer, P. C., Mansour, M., Marczyk, V. R., Roy-Chowdhuri, S., Sherman, S. I., Sousa, L. G., Wang, J. R., Williams, M. D., …, & Cabanillas, M. E. (2026). Characterization of Advanced RAS -driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf366
Vancouver
Hamidi S, Maniakas A, Akhave NS, Banuchi VE, Busaidy NL, Dadu R, et al. Characterization of Advanced RAS -driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgaf366
BibTeX
@article{Hamidi2026,
author = {Hamidi, Sarah and Maniakas, Anastasios and Akhave, Neal S and Banuchi, Victoria E and Busaidy, Naifa L and Dadu, Ramona and Ferrarotto, Renata and Guise, Theresa A and Hofmann, Marie-Claude and Hosseini, S Mohsen and Hu, Mimi I and Iyer, Priyanka C and Mansour, Mena and Marczyk, Vicente R and Roy-Chowdhuri, Sinchita and Sherman, Steven I and Sousa, Luana G and Wang, Jennifer R and Williams, Michelle D and Zafereo, Mark E and Waguespack, Steven G and Cabanillas, Maria E},
title = {Characterization of Advanced RAS -driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgaf366}
}
EUVIMED